Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully representative in age, gender, ethnicity, medical status, or socioeconomic background of the variety of patients who will ultimately receive a medication. This disconnect can lead to post-approval challenges, the most substantial of which could include changes in drug label, dosing, or withdrawal due to severe safety risks that were only observed post-approval. To mitigate these risks and…
